Amarantus Diagnostics was set up separately for a reason.
I expect a "big pharma" partner for the development of the MANF technology.
Down 65% from it's recent high. Time to buy a few shares.
The MANF technology on which Amarantus holds the patents has tremendous potential. the question is to what extent Amarantus can convert that into substantial value for the company's shareholders.
Risk/reward says it's worth buying a few shares here.